Equity Overview
Price & Market Data
Price: $3.20
Daily Change: +$0.08 / 2.50%
Range: $3.06 - $3.29
Market Cap: $9,602,528
Volume: 5,377
Performance Metrics
1 Week: 16.36%
1 Month: 5.26%
3 Months: -15.79%
6 Months: -8.31%
1 Year: -26.69%
YTD: -3.03%
Company Details
Employees: 12
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials indicated for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, currently under phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drops for the treatment of ocular presentation of rheumatoid arthritis. It has collaboration agreement with Théa Open Innovation for the development KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.